Roche is Actively Enhancing its Pipeline
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 77 (Table of Contents)
Published: 6 Nov-2006
DOI: 10.3833/pdr.v2006.i77.433 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche and Plexxikon entered into agreement to develop and commercialize Plexxikon’s PLX4032, targeted cancer therapy. The deal could be worth up to US$706 M to Plexxikon if specific milestones and sales targets are met. Roche also entered into collaborative alliance with InterMune to develop and commercialize InterMune’s drug candidates from HCV protease inhibitor including ITMN-101, which is in preclinical development for treating hepatitis C...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS